Innovent Biologics’ Pemazyre Wins Macau Approval for Cholangiocarcinoma Treatment
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has received marketing approval...
Cancer
Chia Tai Tianqing’s Rovadicitinib Meets Main Goal in Myelofibrosis Trial, Eyes Market Filing
Chia Tai Tianqing, a renowned pharmaceutical company based in China, has declared that it has...
Shanghai Escugen and Anke Bio Partner to Develop ADC Products with EZWi-Fit Platform
Shanghai Escugen, a biopharmaceutical company based in China, has entered into a licensing and cooperation...
ImmuneOnco Receives NMPA Approval for Phase III Clinical Trial of CD47 Inhibitor TIMDARPACEPT
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...
Shanghai Henlius Biotech Advances TIGIT-Targeting HLX53 to Phase II Clinical Trial for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc., (HKG: 2696), a biopharmaceutical company based in China, has received approval...
Sichuan Biokin’s BL-B01D1 Earns Breakthrough Designation for Nasopharyngeal Carcinoma Treatment
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a biopharmaceutical company based in China, has announced...
Innovent Biologics’ IBI133 Receives Tacit Approval for Clinical Trial from China’s CDE
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approval to...
Boehringer Ingelheim Surpasses Bayer in Pharma Sales with EUR 20.8 Billion in 2023
Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing...
Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech
GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has...
AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year...
Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...
Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial
Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial...
Keymed Biosciences Achieves First Dosing in Global Phase III Trial for Claudin 18.2 Targeting ADC
Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced the completion...
Hengrui Pharmaceuticals Gets NMPA Approval for Clinical Study of CDK 4/6 Inhibitor Combo in Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...
Bayer Partners with Hologic to Develop Contrast-Enhanced Mammography Solution for Breast Cancer Diagnosis
Bayer (ETR: BAYN), a multinational pharmaceutical and life sciences company headquartered in Germany, has announced...
Sanofi Explores Sale of Amunix Pharmaceuticals as It Shifts Focus to Immunology
Sanofi (NASDAQ: SNY), the France-based pharmaceutical giant, is reportedly in talks with potential buyers for...
Enhertu Shows 58.3% Response Rate in Phase II Lung Cancer Study, AstraZeneca and Daiichi Sankyo Report
The Phase II DESTINY-Lung05 study results for Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate co-developed by...
Sino Biopharmaceutical to Present Phase II Data for Garsorasib at AACR 2024
Sino Biopharmaceutical Ltd. (HKG: 1177) announced that it will present the results of a Phase...
Roche Secures CE Mark for Ventana HER2 Test, Enhancing Access to AstraZeneca’s Enhertu
Roche (SWX: ROG), based in Switzerland, has received CE marking from the European Commission (EC)...
Jiangsu Hengrui Secures NMPA Approval for Clinical Study of SHR-A2102 and SHR-8068 in Advanced Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical Products...